

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07D 471/04</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/44342</b> <b>(43) International Publication Date:</b> 27 November 1997 (27.11.97)
<b>(21) International Application Number:</b> PCT/KR97/00074 <b>(22) International Filing Date:</b> 2 May 1997 (02.05.97) <b>(30) Priority Data:</b> 1996/16624                      17 May 1996 (17.05.96)                      KR <b>(71) Applicant (for all designated States except US):</b> KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY [KR/KR]; 100, Jang-dong, Yusung-ku, Taejon-si 305-600 (KR). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> CHOI, Joong, Kwon [KR/KR]; 103-604, Hyundae Apt., Doryung-dong, Yusung-ku, Taejon-si 305-340 (KR). KIM, Sung, Soo [KR/KR]; 101-901, Hanwool Apt., Sinsung-dong, Yusung-ku, Taejon-si 305-345 (KR). YUM, Eul, Kyun [KR/KR]; 22-44, Nae-dong, Suh-ku, Taejon-si 302-181 (KR). CHO, Sung, Yun [KR/KR]; 102-803, Hanwool Apt., Sinsung-dong, Yusung-ku, Taejon-si 305-345 (KR). KANG, Seung, Kyu [KR/KR]; 103-1401, Jindale Apt., Worlpyung-dong, Suh-ku, Taejon-si 302-280 (KR). <b>(74) Agent:</b> LEE, Won, Hee; Chunwoo Building, 5th floor, 736, Yoksam-dong, Kangnam-ku, Seoul 135-080 (KR).		<b>(81) Designated States:</b> JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> PROCESS FOR PREPARING 1-ARYL-4-OXOPYRROLO[3,2-c]QUINOLINE DERIVATIVES  <b>(57) Abstract</b>  The present invention relates to a process for preparing 1-aryl-4-oxopyrrolo[3,2-c]quinoline derivatives through reaction of 4-oxofuro[3,2-c]quinoline compounds with aniline compounds under mild conditions in a single step, wherein 1-aryl-4-oxopyrrolo[3,2-c]quinoline derivatives having various substituents may be prepared in high yield, so that the 1-aryl-4-oxopyrrolo[3,2-c]quinoline derivatives may be utilized as an intermediate for producing a reversible inhibitor of gastric acid secretion.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## PROCESS FOR PREPARING


## 1-ARYL-4-OXOPYRROLO[3,2-c]QUINOLINE DERIVATIVES

5

Field of the invention

The present invention relates to a process for preparing 1-aryl-4-oxopyrrolo[3,2-c]quinoline derivatives and, more particularly, to a process for preparing 1-aryl-4-oxopyrrolo[3,2-c]quinoline derivatives represented by structure I which is prepared through the reaction of 4-oxofuro[3,2-c]quinolines with anilines represented by structure III.

15 The formulae I, II and III are as follows:




25

wherein,  $R^1$  may be same or different from  $R^2$  which are respectively hydrogen, lower alkyl group of  $C_1-C_4$ , lower alkoxy group of  $C_1-C_4$ , lower alkylthio group of  $C_1-C_4$ , lower haloalkoxy group of  $C_1-C_4$ , trifluoromethyl group, hydroxyalkoxy group of  $C_1-C_4$ , halogen, or hydroxy group; and

$R^3$  may be same or different from  $R_4$  which are respectively hydrogen, lower alkyl group of  $C_1-C_4$ , lower alkoxy group of  $C_1-C_4$ , lower alkylthio group of  $C_1-C_4$ , lower haloalkyl group of  $C_1-C_4$ , trifluoromethyl group, hydroxy group, amino group, or halogen.

The 1-aryl-4-oxopyrrolo[3,2-c]quinoline derivatives which are prepared according to the present invention are used as intermediates for preparing compounds as represented by structure IV for suppressing gastric acid secretion and many studies have been carried out to prepare the intermediate so far [European Patent Application No. 90-313398.1; European Patent Application No. 88-306583.1; J. Med. Chem., 1990, 33, 527; J. Med. Chem., 1992, 35, 1845].



10 The present invention is to provide a process for preparing compounds as represented by the above structure I which are intermediates in preparation of compounds as represented by the above structure IV which are useful as repressor of the gastric acid secretion.

15 The present invention is to provide a process for preparing compounds as represented by the above formula IV by using the 1-aryl-4-oxopyrrolo[3,2-c]quinoline derivatives which can be prepared in a single reaction step from 4-oxofuro[3,2-c]quinoline with anilines III.


20

#### Prior Art

European Patent Application No. 88-306583.1 and an article [J. Med. Chem., 1992, 35, 1845] disclose a process for preparing 1-aryl-4-oxopyrrolo[3,2-c]

25

quinoline derivatives as represented by the above structure I, which may be summarized as follows:



15 According to the prior art, the 1-aryl-4-oxo pyrrolo[3,2-c]quinoline derivatives I is prepared through reaction of  $(\text{EtO}_2\text{C})_2\text{CHCH}_2\text{CH}_2\text{OEt}$  with anilines as starting material.


20 This method has, however, disadvantages that yield is low while producing the compound I and a large amount of the compounds VI is formed as a by-product.

Further, the method has an inherent limitation that substituents are limited to  $\text{R}^1$  initially present in the starting anilines, and it is impossible to


25 prepare derivatives which has variable substituents.

On the other hand, an article [J. Med. Chem., 1992, 35, 1845] discloses a process for preparing compounds I having substituents R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup>, which may be summarized as follows:


5



10



15



20

According to the above method, 4-oxofuro[3,2-c]quinolines are chlorinated with  $\text{POCl}_3$ , and subject to hydrolysis to obtain compounds VII, so that 1-aryl-4-

oxopyrrolo[3,2-c]quinoline derivatives I having the substituents R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> through the reaction of various anilines with the compounds VII.

5 The method has still disadvantages that a great amount of very toxic POCl<sub>3</sub> has to be used as a reaction reagent and yields are relatively low about 50-70% in each reaction steps. Further, the compound I was obtained in mere prepared 20% yield due to the rather lengthy reaction steps from the compound II.

10 Therefore, the present inventors have developed a novel process to resolve the disadvantages of prior art and to prepare the compounds IV with high biological activity and various substituents through environmentally friendly and simple steps.

15 As a result, the quinoline compound IV may be prepared in a high yield by using 1-aryl-4-oxopyrrolo [3,2-c]quinoline derivatives which may be prepared conveniently in a high yield in such a manner that 4-oxofuro[3,2-c]quinolines II as starting material are  
20 reacted with various anilines as reactant in a single step.

#### SUMMARY OF THE INVENTION

25 The present invention has an objective to



provide a process for preparing 1-aryl-4-oxopyrrolo  
[3,2-c]quinoline derivatives I through a single step to  
react 4-oxofuro[3,2-c]quinolines II as a starting  
material with aniline III.

5           The present invention has another objective to  
provide a process for preparing quinoline compounds IV  
by using the 1-aryl-4-oxopyrrolo[3,2-c]quinoline  
derivatives.

          According to the present invention, the above  
10   objective can be achieved by a process for preparing  
1-aryl-4-oxopyrrolo[3,2-c]quinoline derivatives by  
reacting 4-oxofuro[3,2-c]quinolines with anilines under  
a gentle condition in a single step, wherein 1-aryl-4-  
oxopyrrolo[3,2 -c]quinoline derivatives having various  
15   substituents may be obtained in high yield, so that the  
1-aryl-4-oxopyrrolo[3,2-c]quinoline derivatives may be  
utilized as intermediate for producing a reversible  
inhibitor of gastric acid secretion.


## 20   DETAILED DESCRIPTION OF THE INVENTION

          The present invention will now be described in  
detail with reference to the schemes showing  
embodiments thereof.

25           The present invention relates to a method of

preparing 1-aryl-4-oxopyrrolo[3,2-c]quinoline derivatives represented by structure I which are useful intermediate for compounds represented by structure IV with high biological activity, wherein the 1-aryl-4-oxopyrrolo[3,2-c]quinoline derivatives are prepared by the reaction of aniline compounds represented by structure III with 4-oxofuro[3,2-c]quinolines represented by structure II as starting material.

According to the present invention, the 1-aryl-4-oxopyrrolo[3,2-c]quinoline derivatives with various substituents  $R^1$ ,  $R^2$ ,  $R^3$  and  $R^4$  may be prepared in higher than 70% of yield.



25 In the formulae I, II and III, substituents  $R^1$ ,

R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are defined as above.

The preparation of substituted quinoline compounds, 4-oxofuro[3,2-c]quinoline derivatives II used as starting material are well described in the prior art [1, J. Chem. Sec., 1955, 4284; 2. J. Med. Chem., 1992, 35, 1845].

According to the present invention, solvent is selected from those such as dimethylformamide, dimethyl sulfoxide, diphenyl ether, xylene and the like, or alcoholic solvents such as butyl alcohol, phenol, ethylene glycol monomethyl ether and the like. Preferably, the solvent is selected from alcoholic solvents of which boiling point is 150-280°C, such as phenol, ethylene glycol, diethylene glycol or polyethylene glycol.

The process for preparing 1-aryl-4-oxopyrrolo [3,2-c]quinoline derivatives according to the present invention is preferably performed under inert atmosphere, such as argon or nitrogen.

As a reaction catalyst, p-toluenesulfonic acid and p-toluenesulfonic acid pyridine salt (PPTS) may be used.

Reaction temperature is preferably maintained at 70-300°C, and more preferably, 150-280°C, and reaction time is preferably 7-20 hours.

One to three equivalents of the anilines, as represented by structure III, is effective for preparation 4-oxopyrrolo[3,2-c]quinolines as represented by structure II.


5           Typical examples of the 1-aryl-4-oxopyrrolo[3,2  
-c]quinoline derivatives as represented by structure I  
according to the present invention are shown in table  
1, as follows:

10

&lt;table 1&gt;

	No.	R <sup>1</sup> /R <sup>2</sup>	R <sup>3</sup> /R <sup>4</sup>
5	1	H	2-CH <sub>3</sub>
	2	H	2-OCH <sub>3</sub>
	3	H	2-CH <sub>3</sub> /4-OCH <sub>3</sub>
	4	6-CH <sub>3</sub>	H
	5	6-CH <sub>3</sub>	2-CH <sub>3</sub>
	6	6-CH <sub>3</sub>	2-OCH <sub>3</sub>
	7	6-CH <sub>3</sub>	2-CH <sub>3</sub> /4-OCH <sub>3</sub>
	8	6-CH <sub>3</sub>	2-CH <sub>3</sub> /4-OH
	9	6-CH <sub>3</sub>	2-CH <sub>3</sub> /4-F
	10	6-CH <sub>3</sub>	2-CH <sub>3</sub> /4-CH <sub>3</sub>
10	11	6-CH <sub>3</sub>	2-CH <sub>2</sub> CH <sub>3</sub>
	12	6-OCH <sub>3</sub>	H
	13	6-OCH <sub>3</sub>	2-CH <sub>3</sub>
	14	6-OCH <sub>3</sub>	2-OCH <sub>3</sub>
	15	6-OCH <sub>3</sub>	2-CH <sub>3</sub> /4-OCH <sub>3</sub>
	16	6-OCH <sub>3</sub>	2-CH <sub>3</sub> /4-OH
	17	6-OCH <sub>3</sub>	2-CH <sub>3</sub> /4-F
	18	6-OCH <sub>3</sub>	2-CH <sub>3</sub> /6-CH <sub>3</sub>
	19	6-OCH <sub>3</sub>	3-CH <sub>3</sub>
	20	6-F	2-CH <sub>3</sub>
	21	6-F	2-OCH <sub>3</sub>
	22	6-CF <sub>3</sub>	2-CH <sub>3</sub>
	23	6-OCF <sub>3</sub>	H
	24	6-OCF <sub>3</sub>	2-CH <sub>3</sub>
	25	6-OCF <sub>3</sub>	2-OCH <sub>3</sub>
	26	6-OCF <sub>3</sub>	2-CH <sub>3</sub> /4-OCH <sub>3</sub>
	27	6-OCF <sub>3</sub>	2-CH <sub>3</sub> /4-OH
	28	6-OCF <sub>3</sub>	2-CH <sub>3</sub> /4-F
	29	6-OCF <sub>3</sub>	2-CH <sub>3</sub> /6-CH <sub>3</sub>
	30	6-OCH <sub>2</sub> CF <sub>3</sub>	2-CH <sub>3</sub>
	31	6-OCH <sub>2</sub> CF <sub>3</sub>	2-CH <sub>3</sub> /4-OH
	32	6-SCH <sub>3</sub>	2-CH <sub>3</sub>
	33	6-CH <sub>3</sub> /8-OCH <sub>3</sub>	2-CH <sub>3</sub>
	34	6-CH <sub>3</sub> /8-F	2-OCH <sub>3</sub>
	35	6-OCH <sub>3</sub> /7-F	2-CH <sub>3</sub>
	36	6-OH	2-CH <sub>3</sub>
	37	6-OCF <sub>3</sub> /8-OCH <sub>3</sub>	2-CH <sub>3</sub>
	38	6-OCH <sub>2</sub> CH <sub>2</sub> OH	2-CH <sub>3</sub>
	39	6-CH <sub>2</sub> OH	2-CH <sub>3</sub>
	40	6-CH(OH)CH <sub>3</sub>	2-CH <sub>3</sub>

The 1-aryl-4-oxopyrrolo[3,2-c]quinoline derivatives I which is prepared as above can be used to prepare the compound IV as a reversible inhibitor of the gastric acid secretion through the publicly known method (J. Med. Chem., 1992, 35, 1845)



While the invention has been described by reference to specific examples chosen for purposes of illustration, it should be apparent that the present invention be not limited by the specific disclosure  
5 herein and numerous modifications could be made thereto by those skilled in the art without departing from the basic concept and scope of the invention.

<Example 1>

10 Preparation of 1-(2-methylphenyl)-4-oxo-6-methyl-2,3,4,5-tetrahydropyrrolo[3,2-c]quinoline

4-Oxo-6-methyl-2,3-dihydrofuro[3,2-c]quinoline (201 mg, 1.0 mmol) was dissolved in 10ml of diethylene glycol in a pressure tube and 2-methylaniline (267 $\mu$ l, 2.5mmol) was added under nitrogen. The reaction  
15 mixture was heated at 250°C for 15 hours. The reaction mixture was diluted with 20ml of saline and the aqueous layer was extracted with methylene chloride (15ml x 3).  
20 After washing with water (15ml x 3), the organic layer was dried with anhydrous magnesium sulfate and filtered, and concentrated under reduced pressure. The residue was purified with ethyl acetate as eluent by silica gel chromatography to obtain 237mg of a desired  
25 compound as solid in 82% of yield.

mp: 171-173°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>, 200MHz): δ 2.31(s, 3H), 2.44(s, 3H), 3.05-3.38(m, 2H), 3.76(q, 1H), 4.05-4.23(m, 1H), 6.55-6.75(m, 2H), 7.05-7.39(m, 5H), 8.74(brs, 1H)

5 m/e: 290 (M<sup>+</sup>)

<Example 2>

Preparation of 1-(2-methoxyphenyl)-4-oxo-6-methyl-2,3,4,5-tetrahydropyrrolo[3,2-c]quinoline

10

4-Oxo-6-methyl-2,3-dihydrofuro[3,2-c]quinoline (201mg, 1.0mmol) was dissolved in 10ml of diethylene glycol and 2-methoxyaniline (282μl, 2.5mmol) was added under nitrogen. The reaction mixture was heated at 15 250°C for 15 hours. The reaction mixture was diluted with 20ml of salt water and the aqueous layer was extracted with methylene chloride (15ml x 3). After washing with water (15ml x 3), the organic layer was dried by anhydrous magnesium sulfate and filtered, and 20 concentrated under reduced pressure. The residue was purified with ethyl acetate as eluent by silica gel chromatography to obtain 242mg of desired compound as solid in 79% of yield.

mp: 193-195°C

25 <sup>1</sup>H NMR(CDCl<sub>3</sub>, 200MHz): δ 2.39(s, 3H), 3.15-3.29



(m, 2H), 3.74(s, 3H), 3.68-3.85(m, 1H), 4.05-4.27(m, 1H), 6.05-7.40(m, 7H), 8.41(brs, 1H)

m/e: 360 (M<sup>+</sup>)

5 <Example 3>

Preparation of 1-(2-methyl-4-methoxyphenyl)-4-oxo-6-methyl-2,3,4,5-tetrahydropyrrolo[3,2-c]quinoline

4-Oxo-6-methyl-2,3-dihydropuro[3,2-c]quinoline  
10 (201mg, 1.0mmol) was dissolved in 10ml of diethylene glycol in a pressure tube and 2-methyl-4-methoxyaniline (322μl, 2.5mmol) was added under nitrogen. The reaction mixture was heated at 250°C for 15 hours. The reaction mixture was diluted with 20ml of salt water  
15 and the aqueous layer was extracted with methylene chloride (15ml x 3). After washing with water (15ml x 3), the organic layer was dried by anhydrous magnesium sulfate and filtered, and concentrated under reduced pressure. The residue was purified with ethyl acetate  
20 as eluent by silica gel chromatography to obtain 272mg of desired compound as solid in 85% of yield.

mp: 210-213°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>, 200MHz): δ 2.38(s, 3H), 2.41(s, 3H), 3.07-3.37(m, 2H), 3.68-3.92(m, 1H), 3.83(s, 3H),  
25 4.01-4.18(m, 1H), 6.57-6.89(m, 4H), 7.03-7.29(s, 32H),

8.41 (brs, 1H)

m/e: 320 (M<sup>+</sup>)

<Example 4>

5                   Preparation of 1-(2-methyl-4-hydroxyphenyl)-4-  
-oxo-6-methyl-2,3,4,5-tetrahydropyrrolo[3,2-c]quinoline

4-Oxo-6-methyl-2,3-dihydrofuro[3,2-c]quinoline  
(201mg, 1.0mmol) was dissolved in 10ml of diethylene  
10 glycol in a pressure tube and 4-amino-m-cresol (308mg,  
2.5mmol) was added under nitrogen. The reaction  
mixture was heated at 250°C for 15 hours. The reaction  
mixture was diluted in 20ml of salt water and the  
aqueous layer was extracted by methylene chloride (15ml  
15 x 3). After washing with water (15ml x 3), the organic  
layer was dried by anhydrous magnesium sulfate and  
filtered, and concentrated under reduced pressure.  
The residue was purified with ethyl acetate as eluent  
by silica gel chromatography to obtain 210mg of desired  
20 compound as solid in 81% of yield.

mp: 244-246°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>, 200MHz): δ 2.18(s, 3H), 2.39(s,  
3H), 3.05-3.39(m, 2H), 3.74-3.94(m, 1H), 3.98-4.17(m,  
1H), 6.63-7.27(m, 6H), 8.55(brs, 1H), 9.49(brs, 1H)

25                   m/e: 306 (M<sup>+</sup>)

## &lt;Example 5&gt;

Preparation of 1-(phenyl)-4-oxo-6-methoxy  
-2,3,4,5-tetrahydropyrrolo[3,2-c]quinoline

5

4-Oxo-6-methoxy-2,3-dihydrofuro[3,2-c]quinoline  
(217mg, 1.0mmol) was dissolved in 7ml of phenol and  
aniline (228 $\mu$ l, 2.5mmol) was added under nitrogen.

The reaction mixture was heated at 190°C for 15 hours.

10 The reaction mixture was diluted with 20ml of salt  
water and the aqueous layer was extracted with  
methylene chloride (15ml x 3). After washing with  
water (15ml x 3), the organic layer was dried by  
anhydrous magnesium surface and filtered, and  
15 concentrated under reduced pressure. The residue was  
purified with ethyl acetate as eluent by silica gel  
chromatography to obtain 240mg of desired compound as  
solid in 83% of yield.

mp: 75-77°C

20  $^1\text{H}$  NMR(CDCl<sub>3</sub>, 200MHz):  $\delta$  3.12(t, J=9.2Hz, 2H),  
3.89(s, 3H), 4.03(t, J=9.5Hz, 2H), 6.50(d, J=7.8Hz,  
1H), 6.71-7.33(m, 7H), 8.91(brs, 1H)

m/e: 292 (M<sup>+</sup>)

25

## &lt;Example 6&gt;

Preparation of 1-(2-methylphenyl)-4-oxo-6-methoxy-2,3,4,5-tetrahydropyrrolo[3,2-c]quinoline

- 5                   4-Oxo-6-methoxy-2,3-dihydrofuro[3,2-c]quinoline  
(217mg, 1.0mmol) was dissolved in 10ml of diethylene glycol in a pressure tube and 2-methylaniline (267 $\mu$ l, 2.5mmol) was added under nitrogen. The reaction mixture was heated at 250°C for 15 hours. The reaction  
10 mixture was diluted with 20ml of salt water and the aqueous layer was extracted with methylene chloride (15ml x 3). After washing with water (15ml x 3), the organic layer was dried by anhydrous magnesium sulfate and filtered, and concentrated under reduced pressure.  
15 The residue was purified with ethyl acetate as eluent by silica gel chromatography to obtain 235mg of desired compound as solid in 77% of yield.

mp: 166-168°C

- 20                   <sup>1</sup>H NMR(CDCl<sub>3</sub>, 200MHz):  $\delta$  2.34(s, 3H), 3.11-3.41  
(m, 2H), 3.72-3.91(m, 1H), 3.97(s, 3H), 4.06-4.28(m, 1H), 6.28(d, J=7.9Hz, 1H), 6.73(d, J=8.2Hz, 1H), 6.82(d, J=7.9Hz, 1H), 7.05-7.42(m, 4H), 8.91(brs, 1H)

m/e: 306(M<sup>+</sup>)

J=8.2Hz, 1H), 6.82(d, J=7.9Hz, 1H), 7.05-7.42(m, 4H),  
8.91(brs, 1H)

m/e: 306(M<sup>+</sup>)

5 <Example 7>

Preparation of 1-(2-methoxyphenyl)-4-oxo-6  
-methoxy-2,3,4,5-tetrahydropyrrolo[3,2-c]quinoline

4-Oxo-6-methoxy-2,3-dihydrofuro[3,2-c]quinoline  
10 (217mg, 1.0mmol) was dissolved in 10ml of diethylene  
glycol in a pressure tube and of 2-methylaniline  
(282 $\mu$ l, 2.5mmol) was added under nitrogen. The  
reaction mixture was heated at 250°C for 15 hours. The  
reaction mixture was diluted with 20ml of salt water  
15 and the aqueous layer was extracted with methylene  
chloride (15ml x 3). After layer with water (15ml x  
3), the organic layer was dried with anhydrous  
magnesium sulfate and filtrated to be concentrated  
under reduced pressure. The residue was purified with  
20 ethyl acetate as a development solution according to  
silica gel chromatography to obtain 260mg of desired  
compound as solid in 81% of yield.

mp: 185-188°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>, 200MHz):  $\delta$  3.18(t, J=9.2Hz, 2H),  
25 3.70-4.21(m, 2H), 3.73(s, 3H), 6.44(d, J=8.2Hz, 1H),

6.67-7.34(m, 6H), 8.87(brs, 1H)

m/e: 322 (M<sup>+</sup>)

<Example 8>

5                   Preparation of 1-(2-methyl-4-methoxyphenyl)  
-4-oxo-6-methoxy-2,3,4,5-tetrahydropyrrolo[3,2-c]quin  
oline

4-Oxo-6-methoxy-2,3-dihydrofuro[3,2-c]quinoline  
10 (217mg, 1.0mmol) was dissolved in 10ml of ethylene  
glycol and 4-methoxy-2-methylaniline (322 $\mu$ l, 2.5mmol)  
was added under nitrogen. The reaction mixture was  
heated at 210°C for 15 hours. The reaction mixture  
was diluted with 20ml of salt water and the aqueous  
15 layer was extracted with methylene chloride (15ml x 3).  
After washing with water (15ml x 3), the organic layer  
was dried by anhydrous magnesium sulfate and filtered,  
and concentrated under reduced pressure. The residue  
was purified with ethyl acetate as eluent by silica gel  
20 chromatography to obtain 270mg of desired compound as  
solid in 81% of yield.

mp: 188-191°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>, 200MHz):  $\delta$  2.23(s, 3H),  
3.05-3.35(m, 2H), 3.80(s, 3H), 3.88(s, 3H),  
25 3.80-4.11(m, 2H), 6.27(dd, J=8.1Hz, J2=1.1Hz, 1H),

6.65-6.85(m, 4H), 7.04(d, J=8.6Hz, 1H), 8.83(brs, 1H)

m/e: 336(M<sup>+</sup>)

<Example 9>

5                   Preparation       of 1-(2-methyl-4-fluorophenyl)  
-4-oxo-6-methoxy-2,3,4,5-tetrahydropyrrolo[3,2-c]quin  
oline

4-Oxo-6-methoxy-2,3-dihydrofuro[3,2-c]quinoline  
10   (217mg, 1.0mmol) was dissolved in 10ml of diethylene  
glycol in a pressure tube and (278 $\mu$ l, 2.5mmol) of  
4-fluor-2-methylaniline (278 $\mu$ l, 2.5mmol) was added  
under nitrogen. The reaction mixture was heated at  
250°C for 15 hours. The reaction mixture was diluted  
15   with 20ml of salt water and the aqueous layer was  
extracted with methylene chloride (15ml x 3). After  
washing with water (15ml x 3), the organic layer was  
dried by anhydrous magnesium sulfate and filtered, and  
concentrated under reduced pressure.  
20   The residue was purified with ethyl acetate as eluent  
according to silica gel chromatography to obtain 256mg  
of desired compound as solid in 79% of yield.

mp: 195-198°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>, 200MHz):  $\delta$  2.28(s, 3H),  
25   3.01-3.35(m, 2H), 3.51-3.82(m, 1H), 3.89(s, 3H),

3.88-4.15 (m, 1H), 6.21 (d, J=8.1Hz, 1H), 6.65-7.14 (m, 5H), 8.89 (brs, 1H)

m/e: 324 (M<sup>+</sup>)

5 <Example 10>

Preparation of 1-(3-methylphenyl)-4-oxo-6-methoxy-2,3,4,5-tetrahydropyrrolo[3,2-c]quinoline

4-Oxo-6-methoxy-2,3-dihydrofuro[3,2-c]quinoline  
10 (217mg, 1.0mmol) was dissolved in 7ml of phenol in a pressure tube and 3-methylaniline (268μl, 2.5mmol) was added under nitrogen. The reaction mixture was heated at 190°C for 15 hours. The reaction mixture was diluted with 20ml of salt water and the aqueous layer  
15 was extracted with methylene chloride (15ml x 3). After washing with water (15ml x 3), the organic layer was dried by anhydrous magnesium sulfate and filtered, and concentrated under reduced pressure. The residue was purified with ethyl acetate as eluent by silica gel  
20 chromatography to obtain 230mg of desired compound as solid in 76% of yield.

mp: 155-157°C

<sup>1</sup>H NMR (CDCl<sub>3</sub>, 200MHz): δ 2.32 (s, 3H),  
3.16 (t, J=9.2Hz, 2H), 3.92 (s, 3H), 4.06 (t, J=9.5Hz,  
25 2H), 6.56-7.18 (m, 6H), 7.24 (t, J=6.4Hz, 1H), 8.91 (brs,



1H)

m/e: 306 (M<sup>+</sup>)

<Example 11>

5                   Preparation of 1-(2-methylphenyl)-4-oxo-6-trifluormethoxy-2,3,4,5-tetrahydropyrrolo[3,2-c]quinoline

10   4-Oxo-6-trifluormethoxy-2,3-dihydrofuro[3,2-c]quinoline (272mg, 1.0mmol) was dissolved in 10ml of diethylene glycol and 2-methylaniline (267μl, 1.0mmol) was added under nitrogen. The reaction mixture was heated at 250°C for 15 hours. The reaction mixture was diluted  
15 with 20ml of salt water and the aqueous layer was extracted with methylene chloride (15ml x 3). After washing with water (15ml x 3), the organic layer was dried by anhydrous magnesium sulfate and filtered, and concentrated under reduced pressure. The residue  
20 was purified with ethyl acetate as eluent by silica gel chromatography to obtain 298mg of desired compound as solid in 83% of yield.

mp: 153-156°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>, 200MHz):     δ 2.31(s, 3H),  
25 3.10-3.37(m, 2H), 3.79(q, J=10.2Hz, 1H), 4.07-4.21(m,

1H), 6.58(d, J=8.1Hz, 1H), 6.73(t, J=8.3Hz, 1H),  
7.09-7.36(m, 5H), 8.71(brs, 1H)

m/e: 361(M<sup>+</sup>)

5 <Example 12>

Preparation of 1-(2-methoxyphenyl)-4-oxo-6-trifluormethoxy-2,3,4,5-tetrahydropyrrolo[3,2-c]quinoline

10 4-Oxo-6-trifluormethoxy-2,3-dihydrofuro[3,2-c]quinoline (272mg, 1.0mmol) was dissolved in 10ml of ethylene glycol in a pressure tube and 2-methoxyaniline (282μl, 1.0mmol) was added under nitrogen. The reaction mixture was heated at 210°C for 15 hours.

15 The reaction mixture was diluted with 20ml of salt water and the aqueous layer was extracted with methylene chloride (15ml x 3). After washing with water (15ml x 3), the organic layer was dried by anhydrous magnesium sulfate and filtered, and  
20 concentrated under reduced pressure.

The residue was purified with ethyl acetate as eluent by silica gel chromatography to obtain 286mg of desired compound as solid in 76% of yield.

mp: 171-173°C

25 <sup>1</sup>H NMR(CDCl<sub>3</sub>, 200MHz): δ 3.18-3.31(m,

2H), 3.76(s, 3H), 3.75-3.95(m, 1H), 4.05-4.27(m, 1H), 6.75-7.48(m, 7H), 8.83(brs, 1H)

m/e: 377(M<sup>+</sup>)

5 <Example 13>

1) Preparation of 1-(4-methoxy-2-methylphenyl)  
-4-chloro-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline

10

1-(4-methoxy-2-methylphenyl)-4-oxo-6-methyl-2,3,4,5-tetrahydropyrrolo[3,2-c]quinoline (1.0g, 3.1mmol) was dissolved in 10ml of phosphoryl chloride (POCl<sub>3</sub>) and heated for 2 hours. The reaction mixture was stirred at room temperature for 30 minutes after cooling and addition of ice water. The reaction mixture was extracted with methylene chloride (20ml x 3). After washing with water (15ml x 3), the organic layer was dried by anhydrous magnesium sulfate and filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography to obtain 786mg of desired compound as an oil in 75% of yield.

<sup>1</sup>H NMR(CDCl<sub>3</sub>, 200MHz): δ 2.24(s, 3H), 2.65(s, 3H), 3.05-3.35(m, 2H), 3.85(s, 3H), 3.80-4.11(m, 2H), 6.27(dd, J<sub>1</sub>=8.1Hz, J<sub>2</sub>=1.1Hz, 1H), 6.65-6.89(m, 4H),

7.05 (d, J=8.4Hz, 1H)

m/e: 338 (M<sup>+</sup>)

2) Preparation of 1-(4-methoxy-2-methylamino)-6  
5 -methyl-2,3-dihydropyrrolo[3,2-c]quinoline (IV)

1-(4-methoxy-2-methyl phenyl)-4-chloro-6-methyl  
-2,3-dihydropyrrolo [3,2-c]quinoline (496mg, 1.2mmol)  
was dissolved in 10ml of ethyl alcohol and 5ml of 40%  
10 aqueous methylamine was added. The reaction mixture  
was heated at 170°C for 20 hours in a pressure tube and  
solvent was distilled under reduced pressure. The  
reaction mixture was diluted with 20ml of methylene  
chloride. After washing with water (15ml x 3), the  
15 organic layer was dried by anhydrous magnesium sulfate  
and filtered, and concentrated under reduced pressure.

The residue was purified by silica gel chromatography  
to obtain 324mg of desired compound in 81% of yield.

20 <sup>1</sup>H NMR (CDCl<sub>3</sub>, 200MHz): δ 2.27 (s, 3H), 2.64 (s,  
3H), 2.91-3.20 (m, 2H), 3.11 (d, 3H), 3.65-3.82 (m,  
1H), 3.81 (s, 3H), 4.03-4.21 (m, 2H), 6.68-6.81 (m,  
3H), 6.83-6.90 (m, 2H), 7.20-7.31 (m, 1H)

m/e: 333 (M<sup>+</sup>)

25

## &lt;Example 14&gt;

1) Preparation of 1-(2-methylphenyl)-4-oxo-6-methyl-4,5-dihydropyrrolo[3,2-c]quinoline (IX)

5            1-(2-methylphenyl)-4-oxo-6-methyl-2,3,4,5-tetrahydropyrrolo[3,2-c]quinoline (290mg, 1.0mmol) was dissolved in 20ml of diphenyl ether and 40mg of 5% palladium/carbon was added. The reaction mixture was heated for 4 hours. The reaction mixture was cooled to  
10 the room temperature and directly purified by silica gel chromatography to obtain 245mg of desired compound as solid in 85% of yield.

mp: 224-227°C

<sup>1</sup>H NMR (CDCl<sub>3</sub>, 200MHz): δ 1.93 (s, 3H), 2.81 (s,  
15 3H), 6.93-7.02 (m, 2H), 7.15-7.63 (m, 7H), 8.56 (bra, 1H)

m/e: 288 (M<sup>+</sup>)

2) Preparation of 1-(2-methylphenyl)-4-chloro-6-methylpyrrolo[3,2-c]quinoline (X)

20

1-(2-methylphenyl)-4-oxo-6-methyl-4,5-dihydropyrrolo[3,2-c]quinoline (1.16g, 4.0mmol) was dissolved in 10ml of phosphoryl chloride (POCl<sub>3</sub>) and heated for 2 hours. The reaction mixture was stirred  
25 at room temperature for 30 minutes after cooling and

5H)

m/e: 306 (M<sup>+</sup>)

3) preparation of 1-(2-methylphenyl)-4-[(2-  
5 hydroxyethyl)amino]-6-methylpyrrolo[3,2-c]quinoline  
(III)

1-(2-methylphenyl)-4-chloro-6-methylpyrrolo  
[3,2-c]quinoline (306mg, 1.0mmol) was dissolved in 10ml  
10 of ethanolamine in a pressure tube and heated at 150°C  
for 3 hours. After removal of the reaction solvent  
under reduced pressure and diluted in 20ml of methylene  
chloride, the residue was dried by anhydrous magnesium  
sulfate and filtered, and concentrated under reduced  
15 pressure. The residue was purified by silica gel  
chromatography to obtain 236mg of desired compound as  
solid in 72% of yield.

mp: 187-189°C

<sup>1</sup>H NMR(CDCl<sub>3</sub>, 200MHz): δ 1.93(s, 3H), 2.69(s,  
20 3H), 3.91-3.99(m, 4H), 5.61(bra, 1H), 6.67-7.01(m, 5H),  
7.25-7.52(m, 5H)

m/e: 331 (M<sup>+</sup>)

25

Effect of the invention




As apparent from the above examples, the process for preparing 1-aryl-4-oxopyrrolo[3,2-c]quinoline derivatives I according to the present invention adopts reagents of low cost under mild reaction conditions and the compound I may be prepared from the compound II in a single step. Especially, the preparation process according to the present invention can introduce various substituents such as R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sub>4</sub> which have not been introduced in the prior art. Therefore, according to the present process, the compound IV which is a reversible inhibitor of the gastric acid secretion and has various substituents may be prepared safely and economically in high yield from the 1-aryl-4-oxopyrrolo[3,2-c]quinoline derivatives.

20

25

What is claimed is:

1. A process for preparing 1-aryl-4-oxopyrrolo  
[3,2-c]quinoline derivatives as represented by formula  
5 I, by reaction of 4-oxofuro[3,2-c]quinoline compounds  
as represented by formula II with anilines as  
represented by formula III:



- wherein, R<sup>1</sup> may be same or different from R<sup>2</sup>  
20 which are respectively hydrogen, lower alkyl group of  
C<sub>1</sub>-C<sub>4</sub>, lower alkoxy group of C<sub>1</sub>-C<sub>4</sub>, lower alkylthio  
group of C<sub>1</sub>-C<sub>4</sub>, lower haloalkoxy group of C<sub>1</sub>-C<sub>4</sub>,  
trifluoromethyl group, hydroxyalkoxy group of C<sub>1</sub>-C<sub>4</sub>,  
halogen, or hydroxy group; and  
25 R<sup>2</sup> may same or different from R<sup>1</sup> which are



halogen, or hydroxy group; and

R<sup>3</sup> may same or different from R<sup>4</sup> which are respectively hydrogen, lower alkyl group of C<sub>1</sub>-C<sub>4</sub>, lower alkoxy group of C<sub>1</sub>-C<sub>4</sub>, lower alkylthio group of C<sub>1</sub>-C<sub>4</sub>, lower haloalkyl group of C<sub>1</sub>-C<sub>4</sub>, trifluoromethyl group, hydroxy group, amino group, or halogen.

2. The process as claimed in claim 1, wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are same or different from each other and to be respectively hydrogen, methyl or methoxy.

3. The process as claimed in claim 1, wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are same or different from each other and to be respectively methyl, hydroxy or fluoro.

4. The process as claimed in claim 1, wherein R<sup>1</sup>, and R<sup>2</sup> are respectively hydrogen or hydroxyalkoxy group, and R<sup>3</sup> and R<sup>4</sup> are same or different from each other and to be respectively hydrogen, methyl or methoxy.

5. The process as claimed in claim 1, wherein R<sup>1</sup>, and R<sup>2</sup> are respectively hydrogen or hydroxyalkoxy group, and R<sup>3</sup> and R<sup>4</sup> are same or different from each other and to be respectively methyl, hydroxy or fluoro.

the reaction solvent is selected from dimethyl  
formamide, dimethylsulfoxide, diphenyl ether, xylene,  
butyl alcohol, phenol, ethylene glycol, diethylene  
glycol, triethylene glycol, polyethylene glycol, and  
5 ethylene glycol monomethyl ether.

7. The process as claimed in claim 1, wherein  
the reaction temperature is 70-300°C.

10 8. The process as claimed in claim 1, wherein  
the amount of the aniline compounds is used 1-3  
equivalents for 4-oxofuro[3,2-c] quinoline compounds.

9. A process for preparing the compound as  
15 represented by formula IV by reacting 4-oxofuro[3,2-c]  
quinoline compounds as represented by formula II with  
aniline compounds as represented by formula III in a  
reaction solvent through a single step to obtain a  
compound as represented by formula I, adding POCl<sub>3</sub> to  
20 the compound I to obtain compound as represented by  
formula VIII, and adding alkylamine to the compound  
VIII.

25

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR 97/00074

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC <sup>6</sup> : C 07 D 471/04 According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC <sup>6</sup> : C 07 D 471/00 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched AT, Chemical Abstracts Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Questel: DARC, CAS		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 307 078 A1 (SMITHKLINE BECKMAN) 15 March 1989 (15.03.89), example 9; formula IV; page 6, lines 4-20 (formulas V,VI) (cited in the application).	1-8
A	US 5 420 135 A (BROWN) 30 May 1995 (30.05.95), formula IV (cited in the application).	1
A	Chemical Abstracts, Vol.100, No.5, 30 January 1984 (Columbus, Ohio, USA), page 443, column 1, abstract No.34442u, EIDEN, F. et al.: "Studies on pyran derivatives. Part 97. Cyclization of $\alpha$ -(2-mercapto-benzoyl)- and $\alpha$ -(2-aminobenzoyl)lactams; synthesis of benzothiopyrano[4,3-b]pyrrolinones and pyrrolino- or tetrahydropyridino[3,2-c]quinolinones", & Arch. Pharm. (Weinheim, Ger.) 1983, 316(11), 897-907 (Ger).	1-8
A	Chemical Abstracts, Vol.112, No.7, 12 February 1990 (Columbus, Ohio, USA), page 14, column 1, abstract No.48250q, BROWN, T.H. et al.: "Reversible inhibitors of the gastric (H <sup>+</sup> /K <sup>+</sup> )-ATPase. 1. 1-Aryl-4-methyl-	1-8
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 16 June 1997 (16.06.97)		Date of mailing of the international search report 23 July 1997 (23.07.97)
Name and mailing address of the ISA/ AT AUSTRIAN PATENT OFFICE Kohlmarkt 8-10 A-1014 Vienna Facsimile No. 1/53424/535		Authorized officer Hammer Telephone No. 1/53424/374

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR 97/00074

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>pyrrolo[3,2-c]quinolines as conformationally restrained analogs of 4-(arylamino)quinolines", &amp; J. Med. Chem. 1990, 33(2), 527-33 (Eng). (cited in the application).</p> <p>Chemical Abstracts, Vol.116, No.25, 22 June 1992 (Columbus, Ohio, USA), page 779, column 2, abstract No.255506a, BROWN, T.H. et al.: "Reversible inhibitors of the gastric (H<sup>+</sup>/K<sup>+</sup>)-ATPase. 2. 1-Arylpyrrolo-[3,2-c]quinolines: effect of the 4-substituent", &amp; J. Med. Chem. 1992, 35(10), 1845-52 (Eng).</p> <p>----</p>	1-8

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR 97/00074

**Box I** Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II** Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

- A: Process for preparing 1-Aryl-4-oxo-pyrrolo[3,2-c] quinoline Derivatives (claims 1-8)  
B: Process for preparing 1-Aryl-4-(substituted)amino-pyrrolo [3,2-c]-quinoline Derivatives (claim 9)

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-8

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International application No.

PCT/KR 97/00074

In Recherchenbericht angeführtes Patentdokument Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
EP A1 307078	15-03-89	AT E 79880	15-09-92
		AU A1 19200/89	27-01-89
		DE C0 3874056	01-10-92
		DE T2 3874056	07-01-93
		DK A0 4144/88	22-07-88
		DK A 4144/88	25-01-89
		EP B1 307078	26-08-92
		GB A0 8717644	03-09-87
		JP A2 1040482	10-02-89
		PT A 880330	30-06-88
		PT B 880330	31-03-93
		US A 5051508	24-09-91
		ZA A 8805311	26-07-89
US A 5420135	30-05-95	EP A2 441036	14-08-91
		EP A3 441036	26-03-93
		GB A0 8928281	21-02-90
		JP A2 7215973	15-08-95